Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.69 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.67 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.62 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.61 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41690 | 0.98 | MAOA (0.72) | MAOACHRM2MEN1KMT2ATDP1 | |
| SCHEMBL28054971 | 0.96 | MAOA (0.69) | MAOACHRM2MEN1KMT2ATDP1 | |
| Iodide SCHEMBL3001589 | 0.96 | MAOA (0.69) | MAOACHRM2MEN1KMT2ATDP1 | |
| Ammonia Solution, Strong SCHEMBL28964330 | 0.96 | MAOA (0.69) | MAOACHRM2MEN1KMT2ATDP1 | |
| Bromide SCHEMBL2577914 | 0.96 | MAOA (0.69) | MAOACHRM2MEN1KMT2ATDP1 | |
| Water SCHEMBL28180553 | 0.96 | MAOA (0.69) | MAOACHRM2MEN1KMT2ATDP1 | |
| SCHEMBL16439697 | 0.94 | CHRM2 (0.70) | MAOACHRM2MEN1KMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL28284417 | 0.94 | MAOA (0.73) | MAOACHRM2MEN1KMT2ATDP1 | |
| SCHEMBL29306651 | 0.94 | CHRM2 (0.70) | MAOACHRM2MEN1KMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL1072926 | 0.92 | MAOA (0.77) | MAOACHRM2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417110-B1 | A ONE POT PROCESS FOR PREPARING 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO [4, 4]NON-1-EN-4-ONE (IRBESARTAN) | CTX LIFE SCIENCES PVT LTD (IN) | 2014-05-07 | — | — | EP | claimed |
| US-8609859-B2 | One pot process for preparing 2-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan) | CTX LIFE SCIENCES PVT. LTD. (IN) | 2013-12-17 | — | — | US | claimed |
| US-20120116093-A1 | ONE POT PROCESS FOR PREPARING 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO [4, 4] NON-1-EN-4-ONE (IRBESARTAN) | CTX Life Sciences Pvt. Ltd (IN) | 2012-05-10 | — | — | US | claimed |
| EP-2417110-A2 | A ONE POT PROCESS FOR PREPARING 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO [4, 4]NON-1-EN-4-ONE (IRBESARTAN) | CTX Life Sciences Pvt. Ltd. (IN) | 2012-02-15 | — | — | EP | claimed |
| WO-2011154860-A1 | AN IMPROVED PROCESS FOR PREPARING ILOPERIDONE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2011-12-15 | — | — | WO | claimed |
| WO-2010116380-A2 | A ONE POT PROCESS FOR PREPARING 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO [4, 4] NON-1-EN-4-ONE (IRBESARTAN) | CTX LIFE SCIENCES PVT. LTD. (IN) | 2010-10-14 | — | — | WO | claimed |
| US-20060252940-A1 | CRYSTALLINE 1-[2-(2,4-DIFLUOROPHENYL)-OXIRANYL METHYL]-1H-1,2,4-TRIAZOLE | DR. REDDY'S LABORATORIES, INC. | 2006-11-09 | — | — | US | claimed |
| JP-3054468-A | — | — | None | — | — | JP | disclosed |
| WO-2025099119-A1 | A NOVEL AND HIGHLY COST-EFFICIENT TELESCOPING SYNTHESIS OF 2-METHOXYMETHYL-P-PHENYLENEDIAMINE | WELLA GERMANY GMBH (DE) | 2025-05-15 | — | — | WO | disclosed |
| EP-2934563-B1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) | 2020-07-08 | — | — | EP | disclosed |
| CN-109153846-A | Resin composition, electrophotographic photoreceptor, and electrophotographic apparatus | 出光兴产株式会社 | 2019-01-04 | — | — | CN | disclosed |
| US-9783490-B2 | Antimicrobial compounds, their synthesis and applications thereof | THE SECRETARY OF STATE FOR HEALTH (GB) | 2017-10-10 | — | — | US | disclosed |
| CN-106662820-A | Silicon-containing resist underlayer film forming composition having halogenated sulfonylalkyl group | 日产化学工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| CN-1275123-A | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2000-11-29 | — | — | CN | disclosed |
| JP-H0354468-A | SEPARATION OF STEROID SULFATE IN BLOOD | NISHIKAZE OSAMU | 1991-03-08 | — | — | JP | disclosed |
| EP-0229098-A1 | PLANT GROWTH REGULATING COMPOSITIONS AND PROCESS FOR REGULATING PLANT GROWTH | MéM NÖVéNYVéDELMI éS AGROKéMIAI KÖZPONT (HU) | 1987-07-22 | — | — | EP | disclosed |
| EP-0109039-B1 | BENZO(F)QUINOLINE DERIVATIVES | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-02-25 | — | — | EP | disclosed |
| WO-1986007237-A1 | PLANT GROWTH REGULATING COMPOSITIONS AND PROCESS FOR REGULATING PLANT GROWTH | MÉM NÖVÉNYVÉDELMI ÉS AGROKÉMIAI KÖZPONT (HU) | 1986-12-18 | — | — | WO | disclosed |
| US-4543354-A | Anti-hypertensive 9-aminomethyl-benzo[f]quinoline-3,10-dione derivatives | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0109039-A1 | Benzo(f)quinoline derivatives | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252940-A1 | CRYSTALLINE 1-[2-(2,4-DIFLUOROPHENYL)-OXIRANYL METHYL]-1H-1,2,4-TRIAZOLE | CYP2F1, CYP4B1, CYP3A4 | MAOA 1125/4885CHRM2 2732/4885SIGMAR1 2204/4885 |
| US-20120116093-A1 | ONE POT PROCESS FOR PREPARING 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO [4, 4] NON-1-EN-4-ONE (IRBESARTAN) | PKD1, AGTR1, NPR1 | MAOA 4113/4885CHRM2 1242/4885SIGMAR1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.